 |
4 Products |  |
4 Diseases | | 4 Products |
|
1 Trial |  |
232 News |  |
| «123» |
- || MEDI3726 / ADC Therapeutics, AstraZeneca
PK/PD data, Journal: Multifaceted Bioanalytical Methods for the Comprehensive Pharmacokinetic and Catabolic Assessment of MEDI3726, an Anti-PSMA PBD Antibody-Drug Conjugate. (Pubmed Central) - Apr 1, 2021
P1
Therefore, both heavy-light chain dissociation and the deconjugation of the warhead will affect the activity of MEDI3726. The concentration-time profiles of subjects dosed with MEDI3726 revealed catabolism of the protein scaffold manifested by the more rapid clearance of the Active ADC, while exhibiting minimal deconjugation of the pyrrolobenzodiazepine (PBD) warhead (SG3199).
- ||| camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
I’m very curious how data for ADCT-301 will look in rel/ref HL. A novel drug w/ non-trivial toxicity profile (AIDP in single digit %), in disease where several single agent cytotoxic agents (even CCNU and etoposide) can provide durable disease control with mainly just cytopenias. (Twitter) - Mar 27, 2021
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment closed: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Feb 5, 2021
P2, N=117, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
The concentration-time profiles of subjects dosed with MEDI3726 revealed catabolism of the protein scaffold manifested by the more rapid clearance of the Active ADC, while exhibiting minimal deconjugation of the pyrrolobenzodiazepine (PBD) warhead (SG3199). Recruiting --> Active, not recruiting
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion date, Trial primary completion date, Monotherapy: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - Jan 22, 2021
P1b, N=95, Recruiting, Sponsor: ADC Therapeutics S.A.
Recruiting --> Active, not recruiting Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2022
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion date, Trial initiation date, Trial primary completion date: ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) - Jan 12, 2021
P2, N=10, Not yet recruiting, Sponsor: David Rizzieri, MD
Trial completion date: Jan 2023 --> Nov 2023 | Trial primary completion date: Jul 2022 --> Nov 2022 Trial completion date: Nov 2023 --> Feb 2024 | Initiation date: Dec 2020 --> Mar 2021 | Trial primary completion date: Nov 2023 --> Feb 2024
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
New P2 trial: ADCT-301 in Patients With R/R AML, MDS, or MDS/MPN (clinicaltrials.gov) - Nov 19, 2020
P2, N=10, Not yet recruiting, Sponsor: David Rizzieri, MD
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
P1 data, Journal: Camidanlumab tesirine, an antibody-drug conjugate, in relapsed/refractory CD25-positive acute myeloid leukemia or acute lymphoblastic leukemia: A phase I study. (Pubmed Central) - Nov 6, 2020
P1
The trial was terminated during dose escalation due to programmatic reasons other than safety. Hence, recommended dose was not determined.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] Pharmacokinetic and Pharmacodynamic Correlates from the Phase 1 Study of Camidanlumab Tesirine (Cami) in Patients with Relapsed or Refractory Hodgkin Lymphoma and Non-Hodgkin Lymphoma (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3779;
P2
Given that CD25 is the cognate target of Cami, these data suggest pts with HL achieving CR have higher drug exposure, resulting from lower baseline sCD25, and potential association with lower tumor burden. Although exposure at the 45 µg/kg dose showed moderate inter-patient variability, it was associated with noteworthy, cycle-related modulation in circulating Treg and clear increases in Teff:Treg ratios, thought to favor clinical response.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] Preliminary Results of a Phase 2 Study of Camidanlumab Tesirine (Cami), a Novel Pyrrolobenzodiazepine-Based Antibody-Drug Conjugate, in Patients with Relapsed or Refractory Hodgkin Lymphoma (Channel 7 (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_3201;
P2
Safety was consistent with that reported at Ph 1, with no new safety concerns identified and similar incidence of GBS/polyradiculopathy. Following a positive risk-benefit assessment, the enrollment pause was lifted, and pts continue to be enrolled.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] Combination of Camidanlumab Tesirine, a CD25-Targeted ADC, with Gemcitabine Elicits Synergistic Anti-Tumor Activity in Preclinical Tumor Models (Poster Hall (Virtual Meeting)) - Nov 5, 2020 - Abstract #ASH2020ASH_953;
P1b, P2
Synergistic anti-tumor activity was also demonstrated in a colorectal cancer model using CD25-ADC, a mouse-cross-reactive version of camidanlumab tesirine, in combination with gemcitabine. Altogether, these novel pre-clinical data warrant translation of the combination between camidanlumab tesirine and gemcitabine into the clinic.
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
$ADCT Genmab and ADC Therapeutics Announce Amended Agreement for Camidanlumab Tesirine (Cami) https://t.co/M5Ps3eYG9B (Twitter) - Oct 30, 2020
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers () - Oct 14, 2020 - Abstract #SITC2020SITC_1646;
Combination of CD25-ADC with IL-2 resulted in enhanced anti-tumor activity in both combination groups compared to the respective single agents and the combination was synergistic at the highest IL-2 dose. Conclusions Together, these new preclinical data show novel promising combination regimens for CD25-ADC and other commonly used anti-cancer treatments and they provide rationale for the investigation of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, in similar clinical combinations settings.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] A Tregs depleting, CD25-targeted antibody-drug conjugate synergizes with tumor-targeted radiotherapy and systemic interleukin-2 in pre-clinical models of solid cancers () - Oct 14, 2020 - Abstract #SITC2020SITC_911;
Combination of CD25-ADC with IL-2 resulted in enhanced anti-tumor activity in both combination groups compared to the respective single agents and the combination was synergistic at the highest IL-2 dose. Conclusions Together, these new preclinical data show novel promising combination regimens for CD25-ADC and other commonly used anti-cancer treatments and they provide rationale for the investigation of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, in similar clinical combinations settings.
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment change, Trial completion date, Trial primary completion date, Monotherapy: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - Sep 22, 2020
P1b, N=95, Recruiting, Sponsor: ADC Therapeutics S.A.
Conclusions Together, these new preclinical data show novel promising combination regimens for CD25-ADC and other commonly used anti-cancer treatments and they provide rationale for the investigation of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, in similar clinical combinations settings. N=62 --> 95 | Trial completion date: Jul 2021 --> Jan 2023 | Trial primary completion date: Mar 2021 --> Jul 2022
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
#ADCTherapeutics Announces Publication Highlighting the Potential of #CamidanlumabTesirine (#Cami) as a Novel #Immunooncology Approach for #SolidTumor #Cancers $ADCT https://t.co/arodeMPIXw (Twitter) - Sep 11, 2020
- ||| camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment open: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Aug 7, 2020
P2, N=100, Recruiting, Sponsor: ADC Therapeutics S.A.
N=62 --> 95 | Trial completion date: Jul 2021 --> Jan 2023 | Trial primary completion date: Mar 2021 --> Jul 2022 Active, not recruiting --> Recruiting
- | Review, Journal: Antibody-Drug Conjugates in Breast Cancer: a Comprehensive Review. (Pubmed Central) - Aug 2, 2020
Parallel to this, development of ADCs in breast cancer has suffered other setbacks, including the recent failure of other agents (MM-302) as well as the suspension of a few programs (XMT-1522, ADCT-502) with the overall effect of dampening the impetus of this concept and halting/delaying the progress of drugs associated with it, particularly when immunotherapy is at the center of so many efforts...Finally, breakthroughs are occurring in the orphan triple-negative breast cancer subtype with agents targeting surface proteins. The recent results of Sacituzumab govitecan suggest substantial activity in heavily pre-treated patients and underscore the enduring relevance of antibody drug conjugates as a path towards better outcomes.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
[VIRTUAL] First-in-human study of camidanlumab tesirine (ADCT-301, Cami), an anti-CD25 targeted therapy in patients (pts) with advanced solid tumours: Pharmacokinetics (PK) and biomarker evaluation (On-Demand) - Jul 24, 2020 - Abstract #ESMO2020ESMO_1829;
P1b
Funding: ADC Therapeutics SA. Clinical trial identification: NCT03621982.
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion date, Trial primary completion date: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Jul 22, 2020
P2, N=100, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
Clinical trial identification: NCT03621982. Trial completion date: Jul 2023 --> May 2024 | Trial primary completion date: Nov 2021 --> Aug 2022
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Clinical, P2 data: $ADCT FDA Lifts Partial Clinical Hold on Pivotal Phase 2 Clinical Trial of Camidanlumab Tesirine (Twitter) - Jul 6, 2020
- | Opdivo (nivolumab) / Ono Pharma, BMS
Journal, PD(L)-1 Biomarker, IO biomarker: Novel agents and immune invasion in Hodgkin lymphoma. (Pubmed Central) - Jun 11, 2020
Beyond BV and PD-1 blockade, other novel therapies have demonstrated encouraging preliminary results, including targeted agents, like the CD25 antibody-drug conjugate ADCT-301, and cellular therapies, including CD30 chimeric antigen receptor T cells and Epstein-Barr virus (EBV)-directed cytotoxic T cells. These trials, coupled with the rapid development of prognostic and predictive biomarkers, should drive additional breakthroughs that promise safer and more effective therapies for patients with HL in the future.
- || camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment closed: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Apr 6, 2020
P2, N=100, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
These trials, coupled with the rapid development of prognostic and predictive biomarkers, should drive additional breakthroughs that promise safer and more effective therapies for patients with HL in the future. Recruiting --> Active, not recruiting
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment change, Trial termination: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Feb 26, 2020
P1, N=35, Terminated, Sponsor: ADC Therapeutics S.A.
Recruiting --> Active, not recruiting N=80 --> 35 | Completed --> Terminated; Slow enrollment
- ADCT-502 / ADC Therapeutics
ADCT502 (HER2) (STARLIGHT BALLROOM) - Feb 21, 2020 - Abstract #IASLCLCTT2020IASLC_LCTT_206;
- Xtandi (enzalutamide) / Pfizer, Astellas, Zytiga (abiraterone acetate) / J&J, MEDI3726 / ADC Therapeutics, AstraZeneca
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide. (Poster Board E1) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_562;
P1
Responses were seen at higher doses, but were not durable as pts discontinued due to drug-related AEs. Clinical trial information: NCT02991911.
- Xtandi (enzalutamide) / Pfizer, Astellas, Zytiga (abiraterone acetate) / J&J, MEDI3726 / ADC Therapeutics, AstraZeneca
MEDI3726, a prostate-specific membrane antigen (PSMA)-targeted antibody-drug conjugate (ADC) in mCRPC after failure of abiraterone or enzalutamide. (Poster Board E1) - Dec 22, 2019 - Abstract #ASCOGU2020ASCO_GU_259;
P1
Responses were seen at higher doses, but were not durable as pts discontinued due to drug-related AEs. Clinical trial information: NCT02991911.
- ||| camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion, Trial completion date: ADCT-301-001: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Nov 29, 2019
P1, N=133, Completed, Sponsor: ADC Therapeutics S.A.
Clinical trial information: NCT02991911. Active, not recruiting --> Completed | Trial completion date: Mar 2020 --> Oct 2019
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Dynamic Assembly of a Feedback Complex to Regulate Oncogenic B-Cell Receptor-Signaling (Tangerine 2 (WF2), Level 2 (Orange County Convention Center)) - Nov 7, 2019 - Abstract #ASH2019ASH_3162;
Through these interactions, CD25 mediates negative feedback to BCR signaling in response to antigen-encounter in normal B-cells . Defects in CD25-/- B-cells were not replicated in mice that express CD25 but lack expression of the IL2 cytokine .
- || MEDI3726 / ADC Therapeutics, AstraZeneca
Trial completion: A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Oct 28, 2019
P1, N=33, Completed, Sponsor: MedImmune LLC
Defects in CD25-/- B-cells were not replicated in mice that express CD25 but lack expression of the IL2 cytokine . Active, not recruiting --> Completed
- ADCT-701 / ADC Therapeutics
A multi-omic surfaceome study identifies DLK1 as an epigenetically regulated protein and immunotherapeutic target in neuroblastoma (Board 152: Level 2 - Hall D) - Oct 25, 2019 - Abstract #AACRNCIEORTC2019AACR_NCI_EORTC_678;
DLK1 is an epigenetically regulated immunotherapeutic target in neuroblastoma. ADCT-701 shows potent activity in preclinical models of NB and should be prioritized for clinical development.
- camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Pre-clinical characterization of the mechanism of action of a CD25-targeted pyrrolobenzodiazepine dimer-based antibody-drug conjugate targeting regulatory T cells in solid cancers (Prince George's Exhibition Halls AB) - Oct 2, 2019 - Abstract #SITC2019SITC_1055;
P1b
Together with our previous data [4], these results suggest that sur301's mode of action is at least in part mediated by Tregs depletion while Teffs are not affected. Translation of these pre-clinical data in the clinic is currently being investigated in a phase I trial evaluating the efficacy of camidanlumab tesirine (ADCT-301), a PBD-based ADC targeting human CD25, in patients with selected advanced solid tumors (NCT03621982).
- | MEDI3726 / ADC Therapeutics, AstraZeneca
Preclinical, Journal: Antitumor Activity of MEDI3726 (ADCT-401), a Pyrrolobenzodiazepine Antibody-drug Conjugate Targeting PSMA, in Pre-clinical Models of Prostate Cancer. (Pubmed Central) - Sep 11, 2019
P1
This activity correlated with increased phosphorylated Histone H2AX in tumor xenografts treated with MEDI3726. MEDI3726 is being evaluated in a Phase 1 clinical trial as a treatment for patients with metastatic castrate-resistant prostate cancer (NCT02991911).
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment open: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Sep 9, 2019
P2, N=100, Recruiting, Sponsor: ADC Therapeutics S.A.
MEDI3726 is being evaluated in a Phase 1 clinical trial as a treatment for patients with metastatic castrate-resistant prostate cancer (NCT02991911). Not yet recruiting --> Recruiting
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
New P2 trial: Study to Evaluate the Efficacy and Safety of Camidanlumab Tesirine (ADCT-301) in Patients With Relapsed or Refractory Hodgkin Lymphoma (clinicaltrials.gov) - Aug 11, 2019
P2, N=100, Not yet recruiting, Sponsor: ADC Therapeutics S.A.
- ||| MEDI3726 / ADC Therapeutics, AstraZeneca
$AZN MEDI3726 (PSMA ADC licensed from ADC Therapeutics), previously suspended in phase I, now confirmed discontinued (Twitter) - Jul 25, 2019
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment closed, Trial completion date, Trial primary completion date: ADCT-301-001: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Jul 9, 2019
P1, N=133, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
Not yet recruiting --> Recruiting Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Nov 2019
- || MEDI3726 / ADC Therapeutics, AstraZeneca
Enrollment closed, Enrollment change, Trial completion date, Trial primary completion date: A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jul 5, 2019
P1, N=33, Active, not recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial completion date: Jun 2019 --> Mar 2020 | Trial primary completion date: Jun 2019 --> Nov 2019 Recruiting --> Active, not recruiting | N=224 --> 33 | Trial completion date: Jun 2021 --> Oct 2019 | Trial primary completion date: Jun 2021 --> Oct 2019
- |||| camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Clinical: Agree. For now most of my PD1 progressions respond to ADCT301 then allo, but without it, some patients don’t have a good salvage option. In such case, I discuss pros cons of allo while responding to CPI with patients carefully and let them decide (Twitter) - Mar 25, 2019
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment open, Trial initiation date, Monotherapy: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - Nov 16, 2018
P1b, N=50, Recruiting, Sponsor: ADC Therapeutics S.A.
Recruiting --> Active, not recruiting | N=224 --> 33 | Trial completion date: Jun 2021 --> Oct 2019 | Trial primary completion date: Jun 2021 --> Oct 2019 Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Nov 2018
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment open: ADCT-301-001: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 24, 2018
P1, N=140, Recruiting, Sponsor: ADC Therapeutics S.A.
Not yet recruiting --> Recruiting | Initiation date: Aug 2018 --> Nov 2018 Active, not recruiting --> Recruiting
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion date, Trial primary completion date: ADCT-301-001: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 17, 2018
P1, N=140, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
Active, not recruiting --> Recruiting Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Trial completion: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Oct 17, 2018
P1, N=80, Completed, Sponsor: ADC Therapeutics S.A.
Trial completion date: Dec 2018 --> Jun 2019 | Trial primary completion date: Dec 2018 --> Jun 2019 Active, not recruiting --> Completed
- | ADCT-502 / ADC Therapeutics
Trial completion date, Trial primary completion date: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (clinicaltrials.gov) - Oct 17, 2018
P1, N=21, Terminated, Sponsor: ADC Therapeutics S.A.
Active, not recruiting --> Completed Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment closed, Trial completion date, Trial primary completion date: ADCT-301-001: Study of ADCT-301 in Patients With Relapsed or Refractory Hodgkin and Non-Hodgkin Lymphoma (clinicaltrials.gov) - Oct 5, 2018
P1, N=140, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
Trial completion date: Apr 2018 --> Jul 2018 | Trial primary completion date: Apr 2018 --> Jul 2018 Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018
- | MEDI3726 / ADC Therapeutics, AstraZeneca
Enrollment open, Trial completion date, Trial primary completion date: A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Aug 15, 2018
P1, N=224, Recruiting, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting | Trial completion date: Jun 2018 --> Dec 2018 | Trial primary completion date: Jun 2018 --> Dec 2018 Suspended --> Recruiting | Trial completion date: Oct 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Jun 2021
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
New P1 trial, Monotherapy: Study of ADCT-301 in Patients With Selected Advanced Solid Tumors (clinicaltrials.gov) - Aug 9, 2018
P1b, N=50, Not yet recruiting, Sponsor: ADC Therapeutics S.A.
- | camidanlumab tesirine (ADCT-301) / Genmab, ADC Therapeutics
Enrollment closed: Study of ADCT-301 in Patients With Relapsed/Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia (ALL) (clinicaltrials.gov) - Jun 28, 2018
P1, N=80, Active, not recruiting, Sponsor: ADC Therapeutics S.A.
Suspended --> Recruiting | Trial completion date: Oct 2020 --> Jun 2021 | Trial primary completion date: Oct 2020 --> Jun 2021 Recruiting --> Active, not recruiting
- MEDI3726 / ADC Therapeutics, AstraZeneca
Trial completion date, Trial primary completion date: A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jun 26, 2018
P1, N=224, Suspended, Sponsor: MedImmune LLC
Recruiting --> Active, not recruiting Trial completion date: Jul 2021 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2020
- | ADCT-502 / ADC Therapeutics
Enrollment change, Trial completion date, Trial termination, Trial primary completion date: Study of ADCT-502 in Patients With Advanced Solid Tumors Withhuman Epidermal Growth Factor Receptor-2 (HER2) Expression (clinicaltrials.gov) - Apr 24, 2018
P1, N=21, Terminated, Sponsor: ADC Therapeutics S.A.
Trial completion date: Jul 2021 --> Oct 2020 | Trial primary completion date: Jul 2021 --> Oct 2020 N=278 --> 21 | Trial completion date: Feb 2020 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Feb 2020 --> Apr 2018; Safety
- | MEDI3726 / ADC Therapeutics, AstraZeneca
Trial suspension: A Phase 1/1b Study of MEDI3726 in Adults Subjects With Metastatic Castration Resistant Prostate Cancer (clinicaltrials.gov) - Jan 29, 2018
P1, N=224, Suspended, Sponsor: MedImmune LLC
N=278 --> 21 | Trial completion date: Feb 2020 --> Apr 2018 | Recruiting --> Terminated | Trial primary completion date: Feb 2020 --> Apr 2018; Safety Recruiting --> Suspended